Baseline characteristics of subjects with and without missing SRI-5 data at 52 weeks
| Variable | Missing SRI-5 at 52 weeks | P value | |
| Yes (n=69) | No (n=210) | ||
| MMF, n (%) | 19 (27.5) | 41 (19.5) | 0.16 |
| White race, n (%) | 42 (60.9) | 119 (56.7) | 0.54 |
| Age (years) | 36.9 (12.31) | 39.0 (11.82) | 0.21 |
| Disease duration (years) | 4.68 (5.81) | 4.90 (7.71) | 0.60 |
| Prednisone dose (mg/day) | 10.0 (12.5) | 10.0 (10.0) | 0.15 |
| BILAG score | 15.75 (8.38) | 14.75 (7.11) | 0.33 |
| SLEDAI | 10.68 (4.31) | 10.60 (3.70) | 0.89 |
| PGA | 46.50 (19.59) | 47.09 (16.25) | 0.82 |
| White cell count (×109/L) | 5.68 (2.51) | 5.90 (2.49) | 0.53 |
| Lymphocytes (×109/L) | 1.14 (0.52) | 1.24 (0.61) | 0.23 |
| Neutrophils (×109/L) | 3.71 (2.61) | 3.64 (2.46) | 0.92 |
| CD19 (%) | 11.45 (13.5) | 9.10 (11.1) | 0.14 |
| Haemoglobin (g/L) | 122.0 (13.4) | 123.7 (15.1) | 0.41 |
| C3 (g/L) | 0.97 (0.36) | 1.00 (0.31) | 0.61 |
| C4 (g/L) | 17.2 (15.7) | 15.1 (12.3) | 0.39 |
| Anti-dsDNA (IU/mL) | 120.5 (245.5) | 69.0 (288.0) | 0.99 |
| IgG (g/L) | 14.99 (5.21) | 15.70 (5.49) | 0.35 |
| IgM (g/L) | 0.91 (0.74) | 0.99 (0.78) | 0.27 |
| IgA (g/L) | 2.63 (1.69) | 2.97 (1.56) | 0.12 |
| Anti-SM (U/mL) | 5.5 (21.5) | 5.5 (2.8) | 0.51 |
| Anti-RNP (U/mL) | 5.5 (82.0) | 5.5 (88.0) | 0.25 |
| Anti-SSA/Ro (U/mL) | 5.5 (128.5) | 5.5 (102.0) | 0.77 |
| Anti-SSB/La (U/mL) | 13.75 (29.03) | 21.96 (38.52) | 0.06 |
| Protein to creatinine ratio | 0.07 (0.12) | 0.06 (0.11) | 0.49 |
Values are mean (SD) or median (IQR) depending on distribution of the data.
P values were based on t-tests or Wilcoxon tests for continuous variables, and χ2 tests for categorical variables.
anti-dsDNA, anti-double stranded DNA; anti-RNP, anti-ribonucleoprotein; anti-SM, anti-Smith ; anti-SSA/Ro, anti-Sjögren’s syndrome related antigen A; anti-SSB/La, anti-Sjögren's syndrome type B; BILAG, British Isles Lupus Assessment Group; MMF, mycophenolate mofetil; PGA, Physician Global Assessment; SLEDAI, SLE Disease Activity Index; SRI-5, SLE Responder Index-5.